-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 6, 2021, Adicet Bio announced that a dose-escalation phase 1 clinical trial of the allogeneic, "ready-to-use" CD20 targeting CAR γδ-T cell therapy ADI-001 has obtained positive interim data
γδ-T cells are part of the human innate immune system.
The trial plans to enroll approximately 75 patients with refractory/relapsed B-cell non-Hodgkin lymphoma
In terms of safety, ADI-001 showed good tolerance
The specific results of the test are shown in the following table:
Table source: Reference materials[1]
Reference materials:
[1] Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy.
(The original text has been deleted)